

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31st March, 2015**

(Rs. in Millions)

S. No.	PARTICULARS	Standalone Quarter Ended on		Standalone Year Ended on		Consolidated Year Ended on		
		31/03/2015 Audited	31/12/2014 Unaudited	31/03/2014 Audited	31/03/2015 Audited	31/03/2014 Audited	31/03/2015 Audited	31/03/2014 Audited
1	Net Sales/ Income from operations	985.47	1053.18	1375.11	4504.05	5195.44	4,625.21	5,350.45
	Gross Sales	1.55	1.53	2.17	6.6	8.54	6.60	8.54
	Less : Excise Duty	983.92	1051.65	1372.94	4497.45	5186.9	4,618.61	5,341.91
	(a) Net Sales	4.89	3.99	50.49	21.30	73.65	21.30	73.65
	(b) Other Operating Income	988.81	1,055.64	1,423.43	4,518.75	5,260.55	4,639.91	5,415.56
	Total Income from Operation (Net)							
2	Expenses	635.72	595.00	853.78	2,643.89	3,012.81	2,643.89	3,012.81
	(a) Consumption of raw materials	-22.63	37.48	-35.40	65.28	-23.22	45.55	-12.76
	(b) (Increase)/ Decrease in stock in trade	72.09	68.05	76.87	272.55	255.65	323.62	304.46
	(c) Employee benefits expense	170.82	83.00	96.70	447.41	386.09	459.97	402.17
	(d) Depreciation & amortisation expense	185.13	167.88	194.01	667.70	683.03	735.06	728.78
	(e) Other expenses	1,041.13	951.41	1,185.96	4,096.83	4,314.36	4,208.09	4,435.46
	Total expense	-52.32	104.23	237.47	421.92	946.19	431.82	980.10
3	Profit from operations before other income, finance costs and exceptional items (1-2)	118.50	187.23	334.17	869.33	1,332.28	891.79	1,382.27
	EBIDTA (3+2(d))	2.18	1.16	1.92	5.46	4.06	6.80	4.72
4	Other income	-50.14	105.39	239.39	427.38	950.25	438.62	984.82
5	Profit before finance costs and exceptional items (3+4)	156.46	83.97	73.48	407.03	292.93	412.14	294.04
6	Finance Costs	-206.60	21.42	165.91	20.35	657.32	26.48	690.78
7	Profit after finance costs but before exceptional items (5-6)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8	Exceptional items	-206.60	21.42	165.91	20.35	657.32	26.48	690.78
9	Profit from ordinary activities before tax (7+8)	0.00	0.00	24.82	0.00	47.82	-25.13	47.82
10	Tax expense	-206.60	21.42	141.09	20.35	609.50	51.61	642.96
11	Profit from ordinary activities after tax (9-10)	0.00	0.00	0.00	-25.13	0.00	0.00	0.00
12	Exceptional items (net of tax expense	-206.60	21.42	141.09	45.48	609.50	51.61	642.96
13	Net profit for the period (11-12)	114.42	114.42	114.42	114.42	114.42	114.12	114.42
14	Paid up Equity Share Capital	N. A.	N. A.	N. A.	0.00	4,559.73	4,452.42	4,501.65
15	Reserves excluding revaluation reserves	-18.06	1.87	12.33	3.97	54.19	4.52	57.17
16	E.P.S - Basic not annualised for the qtr	-72.23	7.49	49.32	3.97	54.19	4.52	57.17
	- Annualised							
Part - II								
1	Public Shareholding	7711988	7711988	6437086	7711988	6437086	7711988	6437086
	- Number of Shares	67.40	67.40	56.26	67.40	56.26	67.40	56.26
	- Percentage of Shareholding							
2	Promoters and promoter group shareholding							
a)	Pledged as collateral security to bank	3730000	1430000	2080000	3730000	2080000	3730000	2080000
	- Number of Shares	100.00	38.34	41.56	100.00	41.56	100.00	41.56
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	32.60	12.50	18.18	32.60	18.18	32.60	18.18
	- Percentage of shares (as a % of the total share capital							
b)	Non-Encumbered	0	2300000	2924902	0	2924902	0	2924902
	- Number of Shares	0.00	61.66	58.44	0.00	58.44	0.00	58.44
	- Percentage of shares (as a % of the total share holding of promoter and promoter group							
	- Percentage of shares (as a % of the total share capital	0	20.10	25.56	0	25.56	0	25.56
Particulars								
(B) INVESTOR COMPLAINTS								
	Pending at the beginning of the quarter				NIL			
	Received during the quarter				1			
	Disposed of during the quarter				1			
	Remaining unresolved at the end of the quarter				NIL			

For VENUS REMEDIES LIMITED


 CHAIRMAN & MANAGING DIRECTOR



Notes:

1. The Financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on May 30, 2015.
2. During the year the over all sales and profitability of the company dipped due to dip in sales in countries like Venezuela, Syria, Ukraine, Yemen market, Interest provisions on FCCB & revaluation of FCCB liability due to exchange fluctuation, applicability of new depreciation provisions of Companies Act, 2013, Increase in brand promotion cost of research products of the company, Increase in financial cost. Further the company also lost some of tenders due to stiff price competition
3. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.
3. Investor Complaints pending during the beginning of the quarter-NIL, Received during the quarter-1, Disposed of during the quarter-1, Remaining unresolved at the end of the quarter-NIL.
4. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

**For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED**


(Pawan Chaudhary)

Chairman & Managing Director

Date : 30.05.2015

VENUS REMEDIES LIMITED

Standalone / Consolidated Statement of Assets and Liabilities

Clause 41 of the Listing Agreement For Companies (Other than Banks)

Particulars	Standalone Year Ended on		Consolidated Year Ended on	
	31/03/2015 (Rs In Millions)	31/03/2014 (Rs In Millions)	31/03/2015 (Rs In Millions)	31/03/2014 (Rs In Millions)
A EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share capital	114.42	114.42	114.42	114.42
(b) Reserves and surplus	4547.93	4559.74	4452.42	4475.34
Sub-total – Shareholders' funds	4662.35	4674.16	4566.84	4589.76
2 Non-current liabilities				
(a) Long-term borrowings	1685.6	1395.06	1686.05	1399.84
(b) Deferred tax liabilities (net)	147.78	177.85	147.78	177.85
(c) Other long-term liabilities	6.91	6.69	6.91	6.69
(d) Long-term provisions	37.84	33.14	37.84	33.14
Sub-total – Non-current liabilities	1878.13	1612.74	1878.58	1617.52
3 Current liabilities				
(a) Short-term borrowings	1153.99	1100.77	1153.99	1100.77
(b) Trade payables	257.62	281.42	295.63	312.23
(c) Other current liabilities	476.83	541.23	496.49	551.81
(d) Short-term provisions	19.08	149.89	19.08	171.43
Sub-total – Current liabilities	1907.52	2073.31	1965.19	2136.24
TOTAL – EQUITY AND LIABILITIES	8448.00	8360.21	8410.61	8343.52
B ASSETS				
1 Non-current assets				
(a) Fixed assets	5040.68	4838.89	5219.43	5072.55
(b) Non-current investments	287.36	287.36	0	0
(c) Long-term loans and advances	516.53	549.82	516.53	549.82
Sub-total – Non-current assets	5844.57	5676.07	5735.96	5622.37
2 Current assets				
(a) Current investments				
(b) Inventories	1404.38	1414.57	1428.66	1422.56
(c) Trade receivables	593.7	628.03	632.15	649.86
(d) Cash and cash equivalents	35.21	43.82	36.15	44.07
(e) Short-term loans and advances	570.14	597.72	577.69	604.66
Sub-total – Current assets	2603.43	2684.14	2674.65	2721.15
TOTAL – ASSETS	8448.00	8360.21	8410.61	8343.52